AMGEN INC (AMGN) Stock News
NASDAQ:AMGN - Nasdaq - US0311621009 - Common Stock - Currency: USD
AMGN Latest News, Press Releases and Analysis
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.
deCODE genetics: Mapa completo de recombinación del genoma humano, un gran paso en la genética
/PRNewswire/ -- Los científicos de deCODE genetics/Amgen han elaborado un mapa completo de cómo se mezcla el ADN humano a medida que se transmite durante la...
deCODE genetics: Complete recombination map of the human-genome, a major step in genetics
/PRNewswire/ -- Scientists at deCODE genetics/Amgen have constructed a complete map of how human DNA is mixed as it is passed down during reproduction. The map...
deCODE genetics: Vollständige Rekombinationskarte des menschlichen Genoms, ein wichtiger Schritt in der Genetik
/PRNewswire/ -- Wissenschaftler von deCODE genetics/Amgen haben eine vollständige Karte erstellt, die zeigt, wie die menschliche DNA bei der Weitergabe während...
deCODE genetics : carte de recombinaison complète du génome humain, une étape majeure en génétique
/PRNewswire/ -- Les scientifiques de deCODE genetics/Amgen ont construit une carte complète de la façon dont l'ADN humain est mélangé lorsqu'il est transmis...
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with...
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but that are still worth investing in: CRISPR Therapeutics (NASDAQ: CRSP) and Amgen (NASDAQ: AMGN). CRISPR Therapeutics is a mid-stage biotech specializing in gene editing. It became the first gene-editing treatment that uses the Nobel Prize-winning CRISPR technique, an impressive achievement by CRISPR Therapeutics.
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
3 High-Yield Dividend Stocks to Buy in 2025
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
/PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Monday, January 13, 2025. Robert A. Bradway,...
Lowe's Companies Now #67 Largest Company, Surpassing Amgen
February 14th Options Now Available For Amgen (AMGN)
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.